Background:: Entecavir (ETV) has been shown to be effective in randomized controlled trials in highly selected patients with hepatitis B virus (HBV) infection. This study aimed to evaluate the efficacy of ETV in chronic hepatitis B (CHB) patients in the real-world setting.
Methods:: A total of 233 treatment-naïve, CHB patients who received at least 12 months of ETV treatment were included in this retrospective study. Rates of virological response (VR), hepatitis B s antigen (HBsAg) loss, hepatitis B e antigen (HBeAg) clearance/seroconversion, virological breakthrough, cirrhosis, and hepatocellular carcinoma were evaluated.
Results:: Of 233 patients, 175 patients were male, with mean age of 43 years old, and 135 patients were HBeAg positive. The mean baseline levels of serum alanine aminotransferase and HBV DNA in all patients were 230 U/L and 6.6 log 10 IU/ml, respectively. The mean follow-up period was 28 months. The cumulative rates of achieving VR increased from 3.4% at 3 months to 94.4% at 60 months. Primary nonresponse occurred in 3 (1.3%) patients. Partial VR (PVR) occurred in 61 (26.2%) patients at 12 months. The baseline serum HBV DNA level (hazard ratio [HR], 2.054; P < 0.001) was an independent risk factor for PVR. HBsAg loss did not occur. The cumulative rates of HBeAg clearance increased from 2.2% at 3 months to 28.2% at 60 months. PVR was the significant determinant of HBeAg clearance (HR, 0.341; P = 0.026). Age (HR, 1.072; P = 0.013) and PVR (HR, 5.131; P = 0.017) were the significant determinants of cirrhosis.
Conclusions:: ETV treatment was effective for HBV DNA suppression in this study, but HBsAg loss and HBeAg clearance/seroconversion rates were lower compared with previous clinical trials. PVR was associated with HBeAg clearance and cirrhosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5598331 | PMC |
| http://dx.doi.org/10.4103/0366-6999.213969 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Baseline HBsAg quantitative and CD4 T cell counts are associated with HBsAg loss in people living with HIV/HBV coinfection after combined antiretroviral therapy.
Front Cell Infect Microbiol
March 2025
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Background: Achieving Hepatitis B surface antigen (HBsAg) loss is a significant goal for chronic hepatitis B patients. This study aims to evaluate HBsAg loss in individuals with HIV/HBV coinfection and explore the association of clinical variables with this outcome.
Methods: We enrolled 138 individuals coinfected with HIV/HBV and 480 HBV mono-infected individuals who initiated antiviral treatment.
Mechanisms Underlying Delayed loss of HBeAg and HBV DNA Following HBsAg Seroclearance in PEG-IFNα Treated Patients of chronic hepatitis B.
Emerg Microbes Infect
March 2025
Department of Microbiology &Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Background & Aims: A notable proportion of CHB patients undergoing PEG-IFNα based therapy experience lagged serum HBeAg and/or HBV DNA disappearance in patients achieving HBsAg loss. In this study, we explored the molecular mechanisms behind this clinical phenomenon, offering novel insights into the sustainability of chronic HBV infection.
Methods: Two independent clinical cohorts were enrolled to validate this phenomenon.
Patterns of HBV viremia change and HBsAg loss rate in patients without retreatment within 2 years after entecavir or tenofovir cessation.
Am J Gastroenterol
February 2025
Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Objectives: This study investigated the patterns of HBV viremia change and HBsAg loss rate without retreatment within 2 years after nucleos(t)ide analogues (NA) cessation.
Methods: We enrolled 481 patients who did not receive retreatment in the first 2 years after entecavir or tenofovir disoproxil fumarate (TDF) cessation.
Results: Group I was defined as persistent HBV DNA<2000 IU/mL and normal alanine transaminase (ALT)<40 U/mL (inactive phase); Group II and Group III, as HBV DNA>2000 IU/mL and ALT<40 U/L (Group II) or ALT 40‒80 IU/mL (Group III); Group IV), as HBV DNA>2000 IU/mL and ALT>80 U/mL (active phase).
Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfection.
HIV Med
February 2025
Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Introduction: Hepatitis B surface antigen (HBsAg) loss is a rare event among persons with hepatitis B virus (HBV) monoinfection but seems to happen more frequently in people with HIV (PWH). We assessed the proportion of PWH/HBV coinfection who experienced HBsAg loss during long-term tenofovir-therapy and evaluated its association with quantitative HBsAg (qHBsAg) levels at tenofovir start.
Methods: All Swiss HIV Cohort Study participants with two or more positive HBsAg measurements more than 6 months apart, and at least 4 years of tenofovir-containing antiretroviral therapy (ART), were considered.
Efficacy and safety of GLS4 with entecavir vs entecavir alone in chronic hepatitis B patients: A multicenter clinical trial.
J Infect
March 2025
Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun 130021, China; Jilin Provincial Key Laboratory of Metabolic Liver Diseases, Jilin University, Changchun 130021, China; China-Singapore Belt and Road Joint Laboratory on Liver Disease Research, Changchun 130021, China. Electronic address:
Objectives: GLS4 is a first-in-class hepatitis B virus (HBV) capsid assembly modulator that inhibits HBV replication by interfering with assembly and disassembly of the virus nucleocapsid, this prospective, open-label, comparative, phase 2b trial evaluated the antiviral activity and safety of GLS4/ritonavir (RTV) combined with entecavir in hepatitis B e antigen-positive patients.
Methods: 250 CHB patients were enrolled, including treatment-naïve patients and those interrupted anti-HBV drugs for ≥ 6 months (Part A, n=125), and patients who had taken ETV for ≥1 year and had achieved viral suppression (Part B, n=125). Patients were randomly allocated to receive 120 mg GLS4/100 mg RTV plus 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!